###begin article-title 0
Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
The gene encoding apolipoprotein E (APOE) has been proposed as a candidate gene for vascular complications in Type I diabetes. This study aimed to investigate the influence of three-allelic variations in the APOE gene for the development of diabetic retinopathy and nephropathy.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
Neither APOE alleles frequencies or APOE genotypes frequencies differed between Type I diabetic groups either with or without nephropathy. Similar results were found for patients with and without diabetic retinopathy.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
APOE gene polymorphism does not determine genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
Familial and epidemiological studies have indicated that there is a strong genetic component in the aetiology of diabetic nephropathy in Type I diabetes patients [1,2]. Apolipoprotein E (apoE) was discovered as a plasma protein involved in the metabolism of lipoproteins. Recently, the apolipoprotein E (APOE) gene has been suggested to be a risk factor for the development of micro- and macrovascular complications in diabetic patients.
###end p 8
###begin p 9
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2, E3,</italic>
###xml 74 77 74 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4,</italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
The APOE gene is polymorphic. There are three common alleles, E2, E3, and E4, which code for three major isoforms, resulting in six common genotypes [3,4]. Individuals with apoE2 have higher triglyceride levels and are associated with lower cholesterol compared to individuals with apoE3. Individuals with apoE4 often have elevated plasma cholesterol levels. There is an increased prevalence of cardiovascular disease and particularly Alzheimer's disease [5,6,7].
###end p 9
###begin p 10
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E polymorphism may influence the metabolism of lipoproteins in diabetic patients. Several recent studies have suggested that this polymorphism may be associated with a genetic predisposition for diabetic nephropathy [8,9,10,11]. Thus, APOE is an important candidate gene for the development of microvascular complications in Type I diabetes patients.
###end p 10
###begin p 11
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
The aim of this study was to investigate the influence of APOE gene polymorphism in the development of diabetic nephropathy and retinopathy in Type I diabetes patients.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 13
###begin p 14
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
In this study, all patients were Russians with unrelated Type I diabetes. All diabetic patients for the case-control study were recruited from St.Petersburg Diabetological Centres and had participated in the program "Diabetes mellitus" (which included monitoring of trends and examinations of the determinants of vascular complications in Type I diabetes) carried out in St. Petersburg, Russia since 1997.
###end p 14
###begin p 15
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
The diabetic patients included in this study satisfied the World Health Organization criteria for diabetes mellitus [12]. Glycated haemoglobin (HbAlc) was measured by ion exchange chromatography [13]. At entry the patients had HbAlc levels of 5.7 to 16.8%.
###end p 15
###begin p 16
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
The Type I diabetes groups consisted of 74 subjects with nephropathy and 92 subjects without. The study covered 76 Type I diabetes patients with diabetic retinopathy and 96 patients without. Some subjects had more than one type of diabetic complication, and consequently were analysed in more than one group.
###end p 16
###begin p 17
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
For Type I diabetes patients, all the information was examined for evidence of nondiabetic renal disease. Then questionnaires, medical records, and measurements of albumin excretion were used to determine whether they had diabetic nephropathy. Those patients were considered to have diabetic nephropathy if they were receiving treatment for renal disease and either suffered from persisting proteinuria, or had persisting high albuminuria. Urinary albumin excretion was measured by nephelometry [14]. Nephropathy was defined as a persistent urinary albumin excretion of more than 20 mug/min, or 30 mg/24 h in two out of three consecutive urinalyses. Individuals with no history of nephropathy and no albumin excretion were considered free of nephropathy.
###end p 17
###begin p 18
Fundus ophthalmoscopy and angiofluorography were used to diagnose retinopathy. The diabetic retinopathy group consisted of those showing retinal change, while Type I diabetes control group were those who showed no signs of retinopathy.
###end p 18
###begin title 19
DNA genotyping
###end title 19
###begin p 20
###xml 207 211 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 279 283 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 346 348 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 406 408 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Blood was collected from each individual and stored in ethylenediaminetetraacetic acid (EDTA) tubes at -20degreesC. Genomic DNA was obtained from lysed white blood cells by phenol-chloroform extraction. The APOE gene polymorphism was detected by polymerase chain reaction (PCR). APOE genotyping was performed by the method of Hixson and Vernier [15] using a modified version described by Skobeleva et al. [16].
###end p 20
###begin p 21
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 237 238 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 659 663 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin6</italic>
###xml 940 942 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 968 975 934 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2, E3,</italic>
###xml 980 982 946 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 1001 1005 967 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
The sequence of the sense oligonucleotide primer was 5'-AGATGCGGGCACGGCTGTTCAAGGA-3', and the antisense primer was 5'-CCCTCGCGAGCCCCGGCCTGGTACAC-3' [16]. Each amplification reaction contained 50 mM KCl, 10 mM tris-HCl pH 8.4, 1.5 mM MgCl2, 0.25 muM of each primer, 200 muM dNTP, 10% DMSO, 0.1 mug DNA and 1 U Tag polymerase in a final volume of 20 mul. After denaturation step at 95degreesC for 5 minutes followed by 30 cycle of denaturation at 92degreesC (1 min), annealing at 64degreesC (1 min), extension at 72degreesC (1.5 min) and a final extension at 72degreesC (5 min) using a MiniCycler (MJ Research, Watertown, MA, USA). Genotypes were determined by Hin61 (Fermentas, Vilnius, Lithuania) digestion of a 244-base pair PCR-amplified fragment spanning the two polymorphic sites. The digested DNA fragments were separated using migration on 12% polyacrylamide gels and visualized under UV illumination after ethidium bromide staining [16]. The codominant alleles E2, E3, and E4 determine the six APOE genotypes.
###end p 21
###begin title 22
Statistical testing
###end title 22
###begin p 23
###xml 81 82 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 235 236 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
All data are presented as means +/- SD. Groups were compared using the Student's t test for comparison of two groups for quantitative variables. Allele frequency among control subjects and case subjects were compared using standard Chi2 tests. The difference in genotype frequencies between the groups was tested by Fisher's exact test. A value of P < 0.05 was considered significant.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Clinical characteristics by study group are shown in Table 1. No significant difference was seen between groups with vascular complications (nephropathy and retinopathy) and those without, no matter the age, diabetes duration, age at diabetes onset, and mean HbAlc.
###end p 25
###begin p 26
Clinical characteristics by study groups
###end p 26
###begin p 27
Data are means +/- SD
###end p 27
###begin p 28
The frequency of each genotype in each group conformed to the Hardy -Weinberg equilibrium.
###end p 28
###begin p 29
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
The distribution of the APOE genotypes is shown in Table 2. There was no significant difference in APOE genotype and allele frequency between nephropathic and normoalbuminuric diabetic patients. In this study, no association was found between diabetic retinopathy and APOE polymorphisms. APOE allele frequencies for males and females were similar within groups and in different groups.
###end p 29
###begin p 30
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">of APOE</italic>
Distributionof APOE genotypes and alleles in the case-control association study
###end p 30
###begin p 31
NS, not significant (P value > 0.05)
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALR2</italic>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 584 587 584 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GNB3</italic>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Diabetic nephropathy and diabetic retinopathy are the two most important microangiopathic complications in Type I diabetic patients. Many of the environmental factors that influence the risk of vascular disease are known, but genetic components of the risk for diabetic microangiopathy are poorly understood. Several candidate genes have been investigated to elucidate the genetic factors responsible for vascular complications. The most important of these are the aldose reductase gene (ALR2) [17], the insertion/deletion (I/D) polymorphism of the angiotensin I - converting enzyme (ACE) gene [18,19], C825T polymorphism of the gene encoding the beta-3 subunit of geterotrimeric G-proteins (GNB3) [20,21,22], and C677T polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR) [23].
###end p 33
###begin p 34
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 240 242 240 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2</italic>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 547 549 547 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E4</italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
The genetic polymorphism of apolipoprotein E is associated with lipid abnormalities. Eto et al. [9] suggested that lipid abnormalities may contribute to the development and progression of kidney disease, including diabetic nephropathy. The E2 allele frequency was significantly higher in Type II diabetes patients with nephropathy (7.2%) and with renal failure (9.7%) than in diabetic patients without nephropathy (2.6%) [9]. Apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles entail risk factors [24].
###end p 34
###begin p 35
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE E2</italic>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
The genes responsible for genetic predisposition to vascular complications are still unknown, and little is known about the molecular basis of these complications. The influence of the APOE gene polymorphism to the development of diabetic microangiopathy is uncertain. Chowdhury et al. [10] and Araki et al. [11] demonstrated an association between the presence of the APOE E2 allele and diabetic nephropathy in Caucasian patients with Type I diabetes, although some investigators do not support this association [25,26].
###end p 35
###begin p 36
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
This study elucidated the role of APOE gene polymorphism in the predisposition to diabetic vascular complications. No association ofAPOE gene polymorphism with diabetic nephropathy was demonstrated. This result for diabetic nephropathy confirms the findings of Tarnow et al. [25] and Onuma et al. [26]. It should be mentioned that sample sizes in [10,11] were larger than in this study. With increased sample size comes the possibility to demonstrate an association. But the larger the necessary and sufficient minimal sample size, the weaker the association demonstrated.
###end p 36
###begin p 37
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
We also analysed the association of the APOE gene polymorphism with diabetic retinopathy in the present study. No significant differences were found between groups with and without this vascular complication. A similar result has been shown by Tarnow et al. [25] for diabetic retinopathy.
###end p 37
###begin title 38
Conclusions
###end title 38
###begin p 39
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
The present study found no evidence for a role of the APOE gene polymorphism in genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.
###end p 39
###begin title 40
COMPETING INTERESTS
###end title 40
###begin p 41
None declared.
###end p 41
###begin title 42
Pre-publication history
###end title 42
###begin p 43
The pre-publication history for this paper can be accessed here:
###end p 43
###begin p 44

###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
This work was supported by grant M00-2.6K-359 from Competitive Centre of Basic Science (St.Petersburg, Russia).
###end p 46
###begin p 47
###xml 141 149 <span type="species:ncbi:9606">patients</span>
The author thanks Dr. A.S.Stroikova (St.Petersburg Diabetic Centre, St.Petersburg, Russia) for her valuable consultation and verification of patients' clinical information.
###end p 47
###begin p 48
The author can not but mention agitated discussions with Prof. E.I.Schwartz (St.Petersburg Paediatric Medical Academy, St.Petersburg, Russia).
###end p 48
###begin p 49
The author wishes to thank reviewers Dr. S.Bain and Dr. A.Demaine for careful reading and helpful comments on the manuscript.
###end p 49
###begin p 50
Special thanks to J.Fletcher (Redraft.com, Maidenhead, UK) for redrafting in part and H.Kidd, Ph.D. (Bioscience Editors - GWE, Akarp, Sweden) for editing in part.
###end p 50
###begin article-title 51
Diabetic nephropathy in Type 1 (insulin dependent) diabetes: an epidemiological study
###end article-title 51
###begin article-title 52
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Familial factors determine the development of diabetic nephropathy in patients with IDDM
###end article-title 52
###begin article-title 53
###xml 43 46 <span type="species:ncbi:9606">man</span>
Genetics of the apolipoprotein E system in man
###end article-title 53
###begin article-title 54
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification
###end article-title 54
###begin article-title 55
The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances
###end article-title 55
###begin article-title 56
Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health
###end article-title 56
###begin article-title 57
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex
###end article-title 57
###begin article-title 58
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus
###end article-title 58
###begin article-title 59
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy
###end article-title 59
###begin article-title 60
Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM
###end article-title 60
###begin article-title 61
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies
###end article-title 61
###begin article-title 62
Diabetes Mellitus
###end article-title 62
###begin article-title 63
Measurement of hemoglobin Alc by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated
###end article-title 63
###begin article-title 64
Laser immunonephelometry for routine quantification of urinary albumin excretion
###end article-title 64
###begin article-title 65
###xml 25 30 <span type="species:ncbi:9606">human</span>
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal
###end article-title 65
###begin article-title 66
###xml 24 47 24 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOB100, APOCIII, APOE,</italic>
###xml 128 136 <span type="species:ncbi:9606">children</span>
DNA polymorphism of the APOB100, APOCIII, APOE, and angiotensin-converting enzyme genes and indicators of the lipid spectrum in children and adolescents in St. Petersburg
###end article-title 66
###begin article-title 67
Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes
###end article-title 67
###begin article-title 68
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I - converting enzyme gene
###end article-title 68
###begin article-title 69
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy
###end article-title 69
###begin article-title 70
###xml 30 35 <span type="species:ncbi:9606">human</span>
The C825T polymorphism in the human G-protein beta3 subunit gene is not associated with diabetic nephropathy in Type I diabetes mellitus
###end article-title 70
###begin article-title 71
G protein beta3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy
###end article-title 71
###begin article-title 72
###xml 94 102 <span type="species:ncbi:9606">patients</span>
The C825T polymorphism in the G-protein beta3 subunit gene and diabetic complications in IDDM patients
###end article-title 72
###begin article-title 73
###xml 104 112 <span type="species:ncbi:9606">Patients</span>
Methylenetetrahydrofolate Reductase Gene Polymorphism as a Risk Factor for Diabetic Nephropathy in IDDM Patients
###end article-title 73
###begin article-title 74
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM
###end article-title 74
###begin article-title 75
Parving HH: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy
###end article-title 75
###begin article-title 76
Apolipoprotein E genotypes and risk of diabetic nephropathy
###end article-title 76

